Search research articles

Search research articles

Related Experiment Videos

Developing an algorithm for treating heparin-induced thrombocytopenia.

Bruce A McIntosh¹

¹Department of Pharmacy Practice and Science, University of Kentucky, Lexington, KY 40536, USA. bamcin00@uky.edu

Clinical Advances in Hematology & Oncology : H&O

|September 16, 2005

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Assessment of unintended volume loss of six closed system transfer devices.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2019

Same author

Ximelagatran: an oral direct thrombin inhibitor.

The Annals of pharmacotherapy·2004

Same author

Antithrombotic agents: implications in dentistry.

Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics·2002

See all related articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin therapy. Lepirudin is recommended for treating HIT, except in patients with severe kidney impairment.

Area of Science:

Pharmacology
Hematology
Clinical Medicine

Background:

Heparin-induced thrombocytopenia (HIT) is a life-threatening complication of heparin therapy.
HIT is frequently underdiagnosed, leading to delayed treatment and potential thrombosis.
Effective management strategies are crucial for improving patient outcomes.

Purpose of the Study:

To provide specific treatment recommendations for immune-mediated HIT.
To guide clinicians in managing HIT, with or without associated thrombosis.
To evaluate the efficacy and safety of approved HIT treatments.

Main Methods:

Review of clinical experience in treating HIT patients.
Evaluation of published data on lepirudin and argatroban.

Related Experiment Videos

Development of evidence-based treatment guidelines.

Main Results:

Lepirudin and argatroban are FDA-approved for HIT treatment.
Lepirudin demonstrates favorable efficacy and safety profiles.
Treatment choice depends on patient-specific factors, including renal function.

Conclusions:

Lepirudin is the preferred treatment for HIT in most patients.
Exceptions to lepirudin use include severe or worsening renal dysfunction.
Prompt recognition and appropriate treatment of HIT are vital to prevent severe complications.